Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?
Edward J. Dulac IiiChief Financial Officer2024-03-042,447$7.77
Edward J. Dulac IiiChief Financial Officer2024-01-291,849$5.00
Cindy TahlGeneral Counsel and Secretary2024-01-0910,874$4.37
Edward J. Dulac IiiChief Financial Officer2024-01-097,028$4.37
J. Scott WolchkoPresident and CEO2024-01-0914,391$4.37
Bahram ValamehrChief RD Officer2024-01-0911,271$4.38
Edward J. Dulac IiiChief Financial Officer2024-01-025,182$3.66
Redmile Group LLCDirector2023-12-2644,630$3.72
Redmile Group LLCDirector2023-12-261,655,370$3.72
Redmile Group LLCDirector2023-12-261,655,370$3.72

1 of 2

FATE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?
Redmile Group LLC22.97%26,148,941$94.40MInsider
Redmile Group LLC11.57%13,169,057$47.54MInstitution
Vanguard Group Inc8.71%9,911,007$35.78MInstitution
Amir Nashat8.66%9,852,967$35.57MInsider
Polaris Venture Management Co V LLC8.65%9,841,933$35.53MInsider
Blackrock Inc7.99%9,099,951$32.85MInstitution
Boxer Capital LLC7.22%8,215,910$29.66MInstitution
State Street Corp7.06%8,036,669$29.01MInstitution
Deep Track Capital LP4.90%5,572,607$20.12MInstitution
Bellevue Group Ag4.25%4,839,779$17.47MInstitution

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE67.68%32.32%Net Selling
KYTX57.89%42.11%Net BuyingNet Buying
PGEN24.42%72.43%Net BuyingNet Selling
TBPH58.74%41.26%Net BuyingNet Buying

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 108.08% institutional shareholders, 51.60% Fate Therapeutics insiders, and 0.00% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 26.15M shares representing 22.97% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $94.40M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.